摘要
目的探讨再生障碍性贫血(AA)患者免疫抑制治疗前后外周血血管内皮生长因子(VEGF)、肿瘤坏死因子-α(TNF-α)和干扰素-γ(IFN-γ)表达变化及临床意义。方法 2012年1月至2014年4月收治的30例AA初发患者设为对照组,2014年5月至2016年4月收治的30例经免疫抑制治疗后的AA患者设为观察组,测定患者治疗前后外周静脉血T淋巴细胞亚群(CD_3^+、CD_4^+、CD_8^+、CD_4^+/CD_8^+)、NKT细胞及NK细胞的百分比及CD_3^+淋巴细胞胞浆内TNF-α和IFN-γ水平,比较两组治疗前后相同部位骨髓涂片标本中VEGF表达水平,分析表达情况及临床意义。结果治疗后,观察组T淋巴细胞亚群及NK细胞改善明显优于对照组(P<0.05),CD_3^+/TNF-α+(%)和CD_3^+/IFN-γ+(%)、VEGF表达较对照组明显下调(P<0.05)。结论 AA患者经免疫抑制治疗后可有效的减少胞浆内的TNF-α和IFN-γ的表达,且AA患者中VEGF呈现低表达现象。
Objective To investigate the changes in expressions of peripheral blood VEGF,TNF-αand IFN-(in patients with aplastic anemia(AA)before and after immunosuppressive therapy and their clinical significance.Methods Thirty AA patients treated in our hospital from January 2012 to April 2014 were selected as the control group and another 30 AA patients from May 2014 to April 2016 treated with immunosuppressive therapy as observation group.Peripheral blood T lymphocyte subsets(CD 3+,CD 4+,CD 8+,and CD 4+/CD 8+),NK cells and the percentage of NK cells as well levels of TNF-αand IFN-γin CD 3+lymphocytes were measured before and after treatment.The expression levels of VEGF at the same location of bone marrow smear were measured before and after treatment and compared between the two groups.The clinical significance was analyzed.Results After immunosuppressive therapy,the improvement of T lymphocyte subsets and NK cells in the observation was better than that in the control group(P<0.05).The expressions of CD 3+/TNF-α+(%),CD 3+/IFN-γ+(%)and VEGF were obviously decreased when compared to the control group(P<0.05).Conclusion The immunosuppressive therapy for AA patients can effectively reduce the expressions of TNF-αand IFN-γin the cytoplasm.AA patients show low expression of VEGF.
作者
李敬东
韩效林
杨翠
孙玲
LI Jin-dong;HAN Xiao-lin;YANG Cui;SUN Ling(Department of Hematology,The First Affiliated Hospital,Xinxiang Medical College,Xinxiang 453100,China;Department of Hematology,The First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052,China)
出处
《实用医院临床杂志》
2018年第1期14-17,共4页
Practical Journal of Clinical Medicine
基金
河南省医学科技攻关计划项目(编号:201304030)
作者简介
【通讯作者】孙玲
